&w=3840&q=100)
Inox India share price rises 3% on securing multiple orders worth ₹373 cr
Inox India share price: Cryogenic technology solution provider Inox India share price rose as much as 3.15 per cent to hit an intraday high of ₹1,219.95 per share on Tuesday, June 17, 2025.
At 12:10 PM, Inox India share price was trading 0.62 per cent higher at ₹1,189.90 per share. In comparison, BSE Sensex was trading 0.28 per cent lower at 81,567.80 levels.
Why did Inox India share price rise in trade today?
Inox India share price gained after the company announced that it has secured multiple orders worth ₹373 crore so far in the current financial year, spanning all key business segments—Industrial Gas, Cryo-scientific Solutions, LNG, and Beverage Kegs.
The order breakdown includes ₹151 crore in Cryo-scientific Solutions, ₹141 crore in Industrial Gas, and ₹71 crore in the LNG segment.
'These orders reflect continued trust from global and domestic customers in INOX India's advanced cryogenic systems and capabilities,' Inox India said.
The company has bagged a 'Major' contract from ITER for repairs to the Cryostat Thermal Shield. It has also received several 'Large' and 'Minor' orders for LNG storage tanks, industrial gas storage tanks, transport tanks, dispensers, and disposable cylinders.
Additionally, Inox India secured a 'Minor' order from a German customer for the supply of
beverage kegs.
The order classification by value includes minor (₹10–30 crore), large (₹30–60 crore), significant (₹60–100 crore), major (₹100–150 crore), and mega (above ₹150 crore).
'These orders reinforce our position as a trusted global partner for critical cryogenic solutions. Besides our growing presence across segments and markets, we are equally excited about the growing applications and use-cases for cryogenic solutions, especially in the clean energy space. The positive impact created by our solutions, inspires us to raise the bar of cryogenic excellence. We remain committed to delivering high-quality and innovative cryogenic equipment to customers worldwide,' said Deepak Acharya, chief executive officer, Inox India.
About Inox India
Inox India is a global leader in the manufacturing of cryogenic storage, regasification, and distribution systems for LNG, industrial gases, liquid hydrogen, and cryo-scientific applications.
With a strong presence across India, Brazil, and Europe, the company serves a vast customer base in over 100 countries. Its robust network of after-sales support associates spans 25 countries, ensuring reliable service and support worldwide.
It also plays a pivotal role in advancing India's transition to LNG for industrial and automotive use. The company is recognised for its expertise in design engineering, manufacturing, and delivery of turnkey cryogenic packaged systems.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Stocks to buy under ₹100: Experts recommend four shares to buy today — 18 June 2025
Stocks to buy under ₹ 100: After rising for two straight sessions, the Indian stock market paused and finished lower on Tuesday. The Nifty 50 index ended 92 points lower at 24,853, the BSE Sensex finished 212 points lower at 81,583, while the Bank Nifty index lost 230 points and closed at 55,714. The Nifty Mid-cap and the Nifty Small-cap Indices underperformed the benchmark, where the Nifty Mid-cap 100 Index fell by 0.66%, while the Nifty Small-cap 100 Index corrected by 0.69%. Market breadth remained weak for the fourth consecutive day, with declining stocks outpacing advancing ones, as indicated by a BSE advance-decline ratio of 0.60. Sectorally, it was a sea of red, except for the Nifty IT sector, which managed to stay in positive territory. The Nifty Pharma, Healthcare, Metal, and Consumer Durables indices were among the major losers. The Nifty Pharma Index took a hit, falling nearly 2% following warnings from US President Donald Trump about imminent tariffs on pharmaceutical imports. Speaking on the outlook of the Nifty 50 today, Shiju Kuthupalakkal, Senior Manager of Technical Research at Prabhudas Lilladher, said, "The Nifty 50 index, after witnessing a significant pullback in the last two sessions, found resistance near the 25,000 zone and with profit booking seen witnessed a gradual slide to end near the 24,850 level with bias and sentiment maintained with a cautious approach as of now. As mentioned earlier, the index would have the crucial support zone near the 24,500 zones and would need a decisive move above the 25,200 level to trigger a fresh further rise in the coming days." "The Bank Nifty index succumbed to profit booking during the session and slipped as the day progressed to close near the 55700 level, once again finding resistance near the 56000 zone, a crucial resistance zone. The index has been precariously placed and would need a decisive move above the 56000 zone to turn the bias positive. At the same time, we would need to sustain the near-term support positioned near the 55000 level to maintain the overall trend intact," Shiju Kuthupalakkal of Prabhudas Lilladher said. Regarding intraday stocks for today, market experts — Vaishali Parekh, Vice President of Technical Research at Prabhudas Lilladher; Anshul Jain, Head of Research at Lakshmishree Investment and Securities; and Mahesh M Ojha, AVP — Research at Hensex Securities — recommended buying these three stocks: Medico Remedies, Imagicaaworld Entertainment, and Balmer Lawrie Investments. 1] Medico Remedies: Buy at ₹ 48.50, Target ₹ 53, Stop Loss ₹ 46. 2] Balmer Lawrie Investments: Buy at ₹ 80 to ₹ 81, Targets ₹ 83.50, ₹ 85, ₹ 88, ₹ 90, Stop Loss ₹ 78. 3] Imagicaaworld Entertainment: Buy at ₹ 68.40, Target ₹ 71.50, Stop Loss ₹ 67. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
2 hours ago
- Mint
Buy or sell: Vaishali Parekh recommends three intraday stocks for today — 18 June 2025
Buy or sell stocks: After rising for two straight sessions, the Indian stock market paused and finished lower on Tuesday. The Nifty 50 index ended 92 points lower at 24,853, the BSE Sensex finished 212 points lower at 81,583, while the Bank Nifty index lost 230 points and closed at 55,714. The Nifty Mid-cap and the Nifty Small-cap Indices underperformed the benchmark, where the Nifty Mid-cap 100 Index fell by 0.66%, while the Nifty Small-cap 100 Index corrected by 0.69%. Market breadth remained weak for the fourth consecutive day, with declining stocks outpacing advancing ones, as indicated by a BSE advance-decline ratio of 0.60. Sectorally, it was a sea of red, except for the Nifty IT sector, which managed to stay in positive territory. The Nifty Pharma, Healthcare, Metal, and Consumer Durables indices were among the major losers. The Nifty Pharma Index took a hit, falling nearly 2% following warnings from US President Donald Trump about imminent tariffs on pharmaceutical imports. Vaishali Parekh, Vice President of Technical Research at Prabhudas Lilladher, believes the Indian stock market bias is cautious to positive as the Nifty 50 index is in the 24,500 to 25,200 range. The Prabhudas Lilladher expert said that a bullish or bearish trend could be assumed on the breakage of either side of this range. Speaking on the outlook of the Nifty 50 today, Vaishali Parekh said, "The Nifty 50 index, after witnessing a significant pullback in the last two sessions, found resistance near the 25,000 zone and with profit booking seen witnessed a gradual slide to end near the 24,850 level with bias and sentiment maintained with a cautious approach as of now. As mentioned earlier, the index would have the crucial support zone near the 24,500 zones and would need a decisive move above the 25,200 level to trigger a fresh further rise in the coming days." "The Bank Nifty index succumbed to profit booking during the session and slipped as the day progressed to close near the 55700 level, once again finding resistance near the 56000 zone, a crucial resistance zone. The index has been precariously placed and would need a decisive move above the 56000 zone to turn the bias positive. At the same time, we would need to sustain the near-term support positioned near the 55000 level to maintain the overall trend intact," said Parekh. Parekh said that today, the Nifty's support is at 24,700, while the resistance is at 25,000. The Bank Nifty will have a daily range of 55,200 to 56,200. Regarding intraday stocks for today, Vaishali Parekh recommended buying or selling Cyient, Sun Pharma, and Medico Remedies. 1] Cyient: Buy at ₹ 1330, Target ₹ 1370, Stop Loss ₹ 1300; 2] Sun Pharma: Sell at ₹ 1649, Target ₹ 1600, Stop Loss ₹ 1660; and 3] Medico Remedies: Buy at ₹ 48.50, Target ₹ 53, Stop Loss ₹ 46. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
2 hours ago
- Mint
Recommended stocks to buy today, 18 June, by India's leading market experts
The Indian stock market experienced a volatile session, opening positively but then staying in negative territory due to ongoing geopolitical uncertainties, specifically the US President's warning to Iran. Both the Nifty 50 and BSE Sensex saw early highs but ultimately closed lower, with a bearish candle forming on the Nifty daily chart, indicating a lack of strong buying. With most sectors closing in the red and mid-cap and small-cap segments facing challenges, investors are seeking strategies to generate returns amidst these uncertain market conditions. Here are three stocks to trade, as recommended by NeoTrader's Raja Venkatraman: Why it's recommended: A strong set of Q4 numbers reported ensured that the trends are able to recover. The company also secured strong platform-led client wins in the recent quarter, including full-platform commitments. The long body bullish candle seen on Monday augurs well for the prices. This has led to an improvement in the sentiment. With prices holding firm we can consider going long. Key metrics: P/E: 95.10 | 52-week high: ₹2,190 | Volume: 1.66M. Technical analysis: Support at ₹1,450, resistance at ₹2,150. Risk factors: Market volatility, cyberattacks, and regulatory headwinds. Buy at: CMP and dips to ₹1,780 Target price: ₹1,975-2,050 in 1 month Stop loss: ₹1,760 Also Read: Can this small-cap auto ancillary firm's premium pivot deliver big gains? Why it's recommended: SOMANYCERA's move over the last few days shows that after some muted Q4 numbers, a considerable jump indicates that the trends after being under pressure are now recovering. However, with the nature of the prices seen in the last few days, we can comprehend that the newsflow has already been priced in. The volatile moves seen in the last 3 months are now seen giving up, indicating a possibility of some upward bounce as a rounding pattern is seen forming with volumes. Can look to go long. Key metrics: P/E: 28.31 | 52-week high: ₹872.60 | Volume: 164.02K Technical analysis: Support at ₹477, resistance at ₹685 Risk factors: Geopolitical uncertainties, market trends Buy at: CMP and dips to ₹542 Target price: ₹640-655 in 1 month Stop loss: ₹535 Also Read: Five undervalued power stocks worth adding to your watchlist Why it's recommended: The counter has been steadily moving higher, forming higher highs and higher lows, holding the TS & KS Bands for the past few days. After a brief decline, the stock managed to gather support within the bands to produce a turnaround. After the recent test of the TS & KS Bands, a strong closing on Friday, we can look at some positive vibes to emerge. Key metrics: P/E: 19.29 | 52-week high: ₹256.99 | Volume: 1.51M. Technical analysis: Support at ₹225, resistance at ₹295. Risk factors: Fluctuating demand from domestic tractor segment, which is experiencing pressure due to various factors. Buy at: above ₹261 and dips to ₹248 Target price: ₹279-288 in 1 month Stop loss: ₹243 Here are two stocks to trade today, as recommended by Trade Brains Portal It is well-established in the international market and offers a wide range of products. Well-known brands like Pulsar, KTM, Triumph, Chetak, Dominar, and Avenger are among them. In terms of volume, it ranks second in the domestic motorcycle market and is the biggest exporter of 2Ws from India. With a presence in more than 70 countries, it had a 46.3% market share in the export market and an 18.2% market share in motorcycle sales in India in FY24. Due to high sales of both vehicles and replacement parts, the company's revenue surpassed ₹50,000 for the first time in FY25. The reported income from operations increased by 13.65% from ₹44,870 crore in FY24 to ₹50,995 crore in FY25. With a robust domestic performance in H1 and a comparatively weak H2 that was more than offset by the strong export comeback, volumes increased 7% year over year, demonstrating the adaptability of the company's business strategy to shifting market conditions. In the fourth quarter of FY25, the company sold 943,563 two-wheelers and 159,371 commercial vehicles. In May 2025, there were 332,370 2-wheeler sales and 52,251 commercial vehicle sales; hence, the total sales volume grew by 8% YoY in May. In the upcoming years, the company anticipates the export business unit to increase by at least 20% annually. The company is expected to spend ₹6-7 billion on capital expenditures in FY25-FY26, mostly for maintenance activities, and has committed to delivering ₹1,000 crore of capital expenditures under the PLI plan over a 5-year horizon. They were permitted to increase their export capacity to 50,000 units or more annually by Q4 FY26 for their Dominar brand, which has surpassed several well-known European brands in the personal segment. The business has approved a capital infusion of about ₹2,300 crore into Bajaj Auto Credit Limited, of which ₹955 crore has already been invested. By the end of the next year, it hopes to have invested ₹1,400 crore. This partnership will help the company to overcome the high dependence on the cyclical domestic tractor market. Strong parentage helped the company to increase operational efficiency and capacity expansion, and 70% of exports come from the Kubota network. The company has a market share of 11.8% in the domestic tractor industry. As of March 2025, the agri machinery segment contributes 83% of the total revenue, whereas construction equipment contributes 17%. As of FY25, revenue from operations stood at ₹10,243.9 crore, up by 4.5% as of FY25. EBITDA stood at ₹1,165.3 crore, up by 3% YoY, with a stable EBITDA margin of 11.4% as of FY25. The company saw a jump of 36.6% YoY in tractor volume in exports, compared to industry growth of 4%, as of Q4FY25. Tractor volumes stood at 1,15,554 units as of FY25, up by 1% YoY. The company sold its railway business to Sona BLW Precision Forgings Limited at a lump-sum cash consideration of ₹1,600 crore on 23 October 2024. The company is planning to invest ₹4,500-5,000 crores over the next 3-4 years for setting up a greenfield plant. The greenfield plant will enable the company to integrate various manufacturing processes, leading to an increase in capacity across different verticals for tractor manufacturing, CE manufacturing, spare parts manufacturing, and a dedicated line for manufacturing engines for Kubota. Management expects the tractor industry to grow continuously due to various reasons, like favorable macroeconomic conditions such as a good rabi harvest, better crop prices, and more than average rainfall in 2025, and a sufficient water level in the reservoir. Two stock recommendations by MarketSmith India Raja Venkatraman is co-founder, NeoTrader. His Sebi-registered research analyst registration no. is INH000016223. MarketSmith India is a stock research platform and advisory service focused on the Indian stock market. Trade name: William O'Neil India Pvt. Ltd; Sebi Registration No.: INH000015543 Trade Brains Portal is a stock analysis platform. Its trade name is Dailyraven Technologies Pvt. Ltd, and its Sebi-registered research analyst registration number is INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
